Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion
Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion
复制标题
DOI：
10.1016/j.ajo.2006.12.037
复制
发表时间：
2007-04-01
影响因子：
4.2
通讯作者：
Narayana, Kannan M.
中科院分区：
文献类型：
--
作者：
Pai, Sivakami A.;Shetty, Rohit;Narayana, Kannan M.
目的：研究单次玻璃体内注射贝伐单抗治疗视网膜静脉阻塞所致黄斑水肿的临床、解剖和电生理反应。中心点设计：前瞻性、非随机、干预性病例系列。中心点方法：21例静脉阻塞所致黄斑水肿患者接受贝伐单抗1.25 mg玻璃体腔内注射。视网膜中央静脉阻塞(CRVO)9例，视网膜分支静脉阻塞(BRVO)12例。在基线和随访时进行完整的眼科检查，包括光学相干断层扫描(OCT)。15例患者在基线状态下接受了荧光素血管造影。入选患者分别于基线和随访时进行视网膜电图(ERG)和视觉诱发电位(VEP)检查。结果：基线时平均视力为20/381(中位数，20/400)，1个月后视力改善至平均20/135(中位数，20/60)(P=.001)。12周时，平均视力为20/178(中位数为20/80)(P=.001)。视网膜中央厚度在基线时平均为647~81微米(中位数，609.00公里)，一个月后降至平均293.43微米(中位数，222.00微米)(P=0.001)。12周时平均CRT为320.90微米(中位数为280.00微米)(P=.001)。ERG和VEP均未见波形恶化。中心点：玻璃体腔内注射贝伐单抗可显著改善视网膜静脉阻塞所致的黄斑水肿和视力的短期改善。本报告确认了以前的研究。未观察到眼部毒性和不良反应。然而，需要有足够数量的患者进行前瞻性、随机化、对照的长期研究。
PURPOSE: To investigate clinical, anatomic, and electrophysiologic response after single intravitreal injection of bevacizumab for macular edema attributable to retinal vein occlusion.center dot DESIGN: Prospective nonrandomized, interventional case series.center dot METHODS: Twenty-one patients with macular edema attributable to vein occlusion received intravitreal injection of bevacizumab 1.25 mg. Nine patients had central retinal vein occlusion (CRVO), and 12 patients had branch retinal vein occlusion (BRVO). Complete ophthalmic examination including optical coherence tomog, raphy (OCT) was done at baseline and follow-up visits. Fifteen patients underwent fluorescein angiography at baseline. Selected patients underwent electroretinography (ERG) and visual evoked potential (VEP) at baseline and follow-up. Follow-up was for 12 weeks.center dot RESULTS: At baseline, mean visual acuity was 20/381 (median, 20/400) and showed improvement to mean 20/135 (median, 20/60) after one month, (P = .001). At 12 weeks, mean visual acuity was 20/178 (median, 20/80) (P = .001). The mean central retinal thickness (CRT) was 647-81 mu m (median, 609.00 Km) at baseline and decreased to mean 293.43 mu m (median, 222.00 mu m) at one month (P = .001). At 12 weeks, mean CRT was 320.90 mu m (median, 280.00 mu m) (P = .001). ERG and VEP showed no worsening of the waveforms. There was no significant difference in the visual outcome between the BRVO and CRVO groups.center dot CONCLUSION: Intravitreal injection of bevacizumab appears to result in significant short-term improvement of visual acuity and macular edema secondary to vein occlusion. The present report confirms the previous studies. No ocular toxicity or adverse effects were observed. However, prospective, randomized, controlled long-term studies are required with an adequate number of patients.